Jan 29, 2010 by Brian Orelli, PhDWake Up! You Still Have to Pay AttentionWe already knew Celgene's preliminary numbers, but the conference call offers a look ahead.
Jan 29, 2010 by Brian Orelli, PhDHow to Make Billions of Dollars Without Really TryingLackluster Alzheimer's drugs have been doing it for years.
Jan 29, 2010 by Brian Orelli, PhDAll Grown Up, With Cash to BurnBristol-Myers is all drugs, all the time.
Jan 28, 2010 by Brian Orelli, PhDHow to Make a Billion Bucks in BiotechDrug companies and investors alike have to balance the risk and reward.
Jan 28, 2010 by Brian Orelli, PhDThe Next Amgen? Not Yet.Amylin should get to selling while it waits.
Jan 28, 2010 by Brian Orelli, PhDOnly the Strong Survive at PfizerThe culling of the pipeline isn't as bad as it sounds.
Jan 28, 2010 by Brian Orelli, PhDThe Biggest Development-Stage Drugmaker, EverOK, so it has drugs on the market, but it certainly trades like one.
Jan 28, 2010 by Brian Orelli, PhDHealth-Care Reform Is Dead. Probably.Breaking up the bill doesn't seem like the answer.
Jan 27, 2010 by Brian Orelli, PhDThe Virus-Killer's Killer QuarterThe guidance Gilead Sciences gave wasn't too bad, either.
Jan 27, 2010 by Brian Orelli, PhDHumira or Not, Abbott's on a RollInvestors don't seem to see it that way though.
Jan 26, 2010 by Brian Orelli, PhDIs Victoza's Victory in Vain?Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug.
Jan 26, 2010 by Brian Orelli, PhDTiming Is Everything for AmgenAmgen counts on Prolia for a successful 2010.
Jan 26, 2010 by Brian Orelli, PhDIs the Best of Johnson & Johnson Behind It?This seems like more of a one-time issue to one observer.
Jan 25, 2010 by Brian Orelli, PhDTysabri Updates: All You Have to Do Is AskIt's better than nothing, I suppose.
Jan 25, 2010 by Brian Orelli, PhDNo Way to Hide This Drug ApprovalFDA trumps Acorda on its good news.
Jan 25, 2010 by Brian Orelli, PhDPay-for-Delay Is Under the SpotlightIt helps each side, but governments aren't thrilled with the idea.
Jan 22, 2010 by Brian Orelli, PhDIntuitive Surgical Makes Me a Winner!Hysterectomies are poised to pass prostatectomies as the company's growth driver.
Jan 22, 2010 by Brian Orelli, PhDPfizer's Great Data Won't Do MuchInvestors need to read beyond the headlines.
Jan 22, 2010 by Brian Orelli, PhDUnitedHealth: Beats Earnings, and Gets Beat Down?UnitedHealth was healthy last quarter, but on Wall Street, it's the future that counts.
